Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been named a Leader in the IDC MarketScape for Worldwide Life Science R&D Strategic Consulting Services.
The report highlights that, "TCS is fortifying its capabilities in the med-tech space, and its business transformation capabilities, providing an end-to-end automated, agile, and Intelligent Business 4.0™ framework; end-to-end business operations ownership; value-based consulting; and a cross-business CXO-level focus." It goes on to say "TCS has been recognized for the strategic direction that it brings to its large clinical transformation programs, providing advisory services for regulatory and clinical IT landscape transformation, R&D business capabilities mapping, R&D long-range planning, and portfolio simplification and its expertise in everything related to data."
"The pandemic has brought unprecedented collaboration and acceleration in life sciences companies' R&D initiatives. These companies are partnering with TCS to develop the right transformation strategy, innovatively harness next-gen technologies such as AI, IoT and blockchain to accelerate and expand their R&D programs, enhance business outcomes and achieve purpose-led growth," said Vikram Karakoti, Global Co-Head, Life Sciences, TCS. "This leadership position is a reflection of our strong vision, consulting capabilities, investments in innovation and the resultant market success."
TCS partners with leading life sciences companies to drive innovation and reimagine their R&D processes by leveraging next generation platforms and emerging technologies. TCS offers a full set of services spanning advisory, digital transformation, and cognitive business operations in areas such as M&A and divestitures, IT consulting, supply chain management, digitization of clinical trials, paperless and integrated lab environment, blockchain-enabled clinical supply chain, AI-enabled case processing, and discovery collaboration. The solutions use a combination of artificial intelligence, cognitive computing capabilities, robotic process automation, IoT and cloud to fully digitize the life sciences value chain.
Using its Business 4.0 thought leadership framework, deep industry expertise, and intellectual property, TCS' life sciences consultants work collaboratively with customers and harness collective knowledge to draw up transformation roadmaps and design technology-led solutions with measurable impact in areas such as patient centricity, accelerated drug discovery, and clinical development.
TCS has also invested heavily in research and innovation capabilities in the life sciences domain. Its genomics labs offer capabilities such as DNA sequencing, marker validation, and translational research.
A critical transformation lever is TCS' flagship intellectual property, TCS ADD, a cloud-native, cognitive platform that reimagines the end-to-end drug development value chain using digital technologies to enhance patient and user experience, and improve clinical trial outcomes. The platform leverages the TCS Decision Fabric™ AI engine and spans data standardization, data management, analytics and insights, safety, regulatory, supply management, patient and site engagement, and devices and connections.
Shares of Tata Consultancy Services Ltd. was last trading in BSE at Rs. 3954.8 as compared to the previous close of Rs. 3885.15. The total number of shares traded during the day was 130664 in over 5570 trades.
The stock hit an intraday high of Rs. 3980 and intraday low of 3866.45. The net turnover during the day was Rs. 514226909.